The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Antiphospholipid Syndrome: Management & Future Directions

Antiphospholipid Syndrome: Management & Future Directions

December 4, 2020 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ACR Convergence graphicACR CONVERGENCE 2020—Maria Laura Bertolaccini, PhD, postdoctoral research associate, King’s College London, started off the session on antiphospholipid syndrome (APS) talking about novel and non-criteria antibodies for APS and their potential to predict thrombotic episodes. Currently, three antibody tests are required for the diagnosis and classification of APS: lupus anticoagulant, anti-cardiolipin and anti-β2 glycoprotein I (anti-β2GPI). These three, although widely available, are not sufficient to identify all patients with APS. In searching for new diagnostic antibodies, researchers have found that IgG antibodies that recognize epitope Gly40-Arg43 in domain I of β2-gycoprotein I not only cause lupus anticoagulant, but their presence correlates strongly with thrombosis. This area of domain I is likely also covered by a carbohydrate chain in solution, making the epitope cryptic.

You Might Also Like
  • Risk Assessment & Treatment in Antiphospholipid Syndrome Patients
  • New Assays May Help in the Diagnosis & Management of Antiphospholipid Syndrome
  • Antiphospholipid Syndrome
Also By This Author
  • Data Accumulate to Suggest HLA-B27 Status May Drive Axial Phenotype in SpA

Dr. Bertolaccini

Antibodies for APS
A 2006 study found that pathogenic anti-β2-glycoprotein antibodies recognize domain I of β2 glycoprotein only after a conformational change.1 The anti-β2-GPI antibodies thus bind an epitope that is only exposed on β2-GPI when bound to a negatively charged surface. These antibodies to domain I of β2 glycoprotein (anti-DI) have been shown to increase the hazard ratio for APS and to be associated with thrombosis and pregnancy morbidity. Additional studies in animal models suggest these anti-DI antibodies are pathogenic. Nevertheless, because they are more specific but less sensitive than anti-β2GPI, their presence does not increase the diagnostic yield and their routine clinical use is still debated.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Data on antibodies to other domains of β2GPI were also presented.

Dr. Bertolaccini discussed antibodies to domain IV/V of β2GPI and explained that available data show these antibodies fail to induce thrombosis in a rat model. That said, preliminary evidence suggests that the anti-DI to anti-D IV/V ratio may be a useful new biomarker for APS that is helpful for identifying pathogenic anti-β2GPI.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

A lot of interest has been directed to antiphosphatidylserine/prothrombin antibodies (aPS/PT). Animal models have revealed aPS/PT antibodies to be pathogenic and an independent risk factor for thrombosis. The antibodies are independent of the presence of lupus anticoagulant and their risk is additive to other routine antiphospholipid antibodies. Dr. Bertolaccini explained that, along with lupus anticoagulant and anti-β2 glycoprotein I, aPS/PT offer the best diagnostic accuracy for APS and they may be useful in identifying additional patients with APS.

Treatment of Thrombotic APS
Thomas Ortel, MD, PhD, chief of the Division of Hematology in the Department of Medicine at Duke University Medical Center, Durham, N.C., then presented his current recommendations for the treatment of thrombotic APS, as well as evidence against the use of direct oral anticoagulants. He highlighted three key references that addressed the treatment of thrombotic APS.

Pages: 1 2 3 | Single Page

Filed Under: ACR Convergence, Conditions, Meeting Reports Tagged With: ACR Convergence 2020, Antiphospholipid Antibody Syndrome (APS), Hughes Syndrome, meeting reports

You Might Also Like:
  • Risk Assessment & Treatment in Antiphospholipid Syndrome Patients
  • New Assays May Help in the Diagnosis & Management of Antiphospholipid Syndrome
  • Antiphospholipid Syndrome
  • Advancements in Diagnosis, Treatment for Antiphospholipid Syndrome

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)